Overall, these findings suggest that the combination of ERBB2 inhibitor Afatinib and Anti-PD1 therapy is more promising approach for the treatment of HCC compared to traditional monotherapy. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.